JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $179 from $171 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ Earnings Call Highlights Robust Growth
- Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression
- Neurocrine price target raised to $184 from $170 at Needham
- Neurocrine falls after DOJ sends Ingrezza investigative demand
- Neurocrine pullback despite ‘big quarter’ a buying opportunity, says RBC Capital